The knockdown of FOXO3 results in the increased CSC self-renewal capacity in prostate [95], glioblastoma [96], ovarian [97], breast [98], liver, and colorectal cancer [99], whereas leukemia needs FOXO3 for stem cell maintenance [100]. The gene discussed is FOXO3; the disease is colorectal cancer.